Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2021 | $11.00 → $10.00 | Buy | Roth Capital |
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
DEFA14A - Vivos Therapeutics, Inc. (0001716166) (Filer)
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Vivos' management will conduct a conference call at 5:00 p.m. (Eastern Time) on November 14, 2024 to review the results and provide an overview of Vivos' recent achievements and developments. To
Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today reported financial results and operating highli
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Vivos' management will conduct a conference call at 5:00 p.m. (Eastern Time) on November 14, 2024 to review the results and provide an overview of Vivos' recent achievements and developments. To
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announced the American Medical Association (AMA) has issued new CPT® medical codes applicable to all Vivos CARE oral medical devices, which will become effective January 1, 2025. Vivos Chairman and CEO, Kirk Huntsman, stated, "This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Ou